Understanding the DEXA Study on GLP 1 and Diet
Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of type 2 diabetes mellitus and obesity. However, recent studies have raised concerns about the potential risks of GLP-1 medications on bone health and skeletal disorders, such as osteoporosis.
What is GLP-1 and How Does it Affect the Body?
GLP-1 is a naturally occurring hormone in the body that helps regulate blood sugar levels and appetite. GLP-1 receptor agonists, such as semaglutide and liraglutide, mimic the action of GLP-1 to improve glucose control and reduce hunger. However, some studies have suggested that GLP-1 medications may increase the risk of osteoporosis and bone fractures in obese individuals.
DEXA Scans: A Measure of Body Composition
Dual-energy X-ray absorptiometry (DEXA) scans are a non-invasive imaging technique that allows healthcare providers to measure bone mineral density (BMD) and body composition. A DEXA scan can differentiate between bone tissue and soft tissue, providing a comprehensive understanding of body composition and tracking changes over time.
Understanding the Risks of GLP-1 Medications
Recent studies have suggested that GLP-1 medications may increase the risk of osteoporosis and bone fractures in obese individuals. A study published in the Journal of the American Medical Association (JAMA) found that GLP-1 medications were associated with a higher risk of osteoporosis and gout. Another study published in the British Medical Journal (BMJ) found that GLP-1 medications were linked to a higher risk of bone fractures and osteoporosis.
